All In Biotech

Drug Trial Radar · NCT00035555

Study Comparing the Safety and Efficacy of Belatacept With That of Cyclosporine in Patients With a Transplanted Kidney

Phase II/III, Open-Label, Randomized, Controlled, Multiple-Dose Study of Efficacy and Safety of BMS-224818 (Belatacept) as Part of a Quadruple Drug Regimen in First Renal Transplant Recipients

Last checked: Nov 20, 2026Latest source record: Jan 13, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 230 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

230

Actual

Start

Mar 2001

Primary completion

Jan 2004

Study completion Jul 2012

Sponsor

Lead sponsor
Bristol-Myers SquibbBristol Myers Squibb (BMY)
Sponsor type
Industry
First posted
May 6, 2002

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Prevention
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine whether treatment with Belatacept (BMS-224818) is as efficacious as treatment with cyclosporine at preventing acute rejection and with a superior safety/tolerability profile (better kidney function and blood pressure, fewer lipid problems, less diabetes mellitus).

Conditions

  • Graft Rejection
  • Kidney Transplantation
  • Renal Transplantation

Interventions

  • BelataceptDrug

    Solution, intravenous

  • CyclosporineDrug

    Oral, capsule

  • Mycophenolate mofetil (MMF)Drug

    Oral, capsule

  • CorticosteroidsDrug

    Corticosteroids given daily, orally or intravenously (IV). Day of transplant (Day 1): methylprednisolone, 500 mg, given IV on arrival in operating room; Day 2: methylprednisolone, 250 mg, given IV once daily; Day 3: prednisone, 100 mg, given orally once daily; Day 4: prednisone, 50 mg, given orally once daily; Days 5 through 30: prednisone, 25 mg, given orally once daily; Days 31-44: prednisone, 22.5 mg, given orally once daily; Days 45-58: prednisone, 20 mg, given orally once daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With an Episode of Clinically-suspected and Biopsy-proven Acute Rejection (CSPAR)Time frame: By Month 6 posttransplant (From Day 1 to Month 6)

Locations

12 sites in 1 country. Site status is shown where the registry gives one.

  • Univ. of Calif. - San Francisco

    San Francisco, California

  • Emory Univ. School of Medicine

    Atlanta, Georgia

  • Johns Hopkins University

    Baltimore, Maryland

  • Massachusetts General Hospital

    Boston, Massachusetts

  • Mayo Clinic

    Rochester, Minnesota

  • Univ. of Nebraska Medical Center

    Omaha, Nebraska

  • Saint Barnabas Medical Center

    Livingston, New Jersey

  • Mount Sinai Medical Center

    New York, New York

  • Univ. of Pennsylvania

    Philadelphia, Pennsylvania

  • Medical Univ. of South Carolina

    Charleston, South Carolina

  • Baylor Univ. Medical Center

    Dallas, Texas

  • Univ. of Wisconsin

    Madison, Wisconsin

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.